High efficacy of azacitidine combined with homoharringtonine, idarubicin, and cytarabine in newly diagnosed patients with AML: A single arm, phase 2 trial

INTRODUCTION: This study aims to evaluate the efficacy and safety of the novel combination of Aza and HIA as the frontline induction therapy in newly diagnosed AML patients eligible for intensive chemotherapy (IC) (registered on ClinicalTrials.gov, number NCT04248595). METHODS: Aza (75mg/m2/d on day...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jun, Huang, Yanqing, Hou, Yue, Gu, Yan, Song, Chunhua, Ge, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773133/
https://www.ncbi.nlm.nih.gov/pubmed/36568250
http://dx.doi.org/10.3389/fonc.2022.1069246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773133/
https://www.ncbi.nlm.nih.gov/pubmed/36568250
http://dx.doi.org/10.3389/fonc.2022.1069246

Ejemplares similares